Why Is LATIGO BIOTHERAPEUTI (LTGO) Stock Up Today?

LTGO stock rose 5.45% to $23.22 on Friday, driven by a surge in analyst coverage and a series of new buy ratings from major firms. The stock opened with a 4.6% gap up and saw a volatile session with a high of $23.77 and a low of $21.25. The rally follows multiple institutions initiating coverage with positive outlooks, signaling growing confidence in the company’s therapeutic pipeline.

What Happened

Jefferies initiated coverage on Latigo Biotherapeutics with a Buy rating, setting a $50 price target. Goldman Sachs also began coverage with a Buy rating, citing the company’s potential in the pain drug sector. Leerink and Guggenheim joined the trend, with Leerink assigning an Outperform rating and a $36 price target, while Guggenheim also issued a Buy rating with a $50 price target. These actions have generated momentum, with the stock responding to the influx of bullish analyst commentary. The stock had previously opened at $23.03 and traded as high as $23.77 during the session, reflecting strong investor reaction to the coverage.

What The Data Shows

The stock has traded between $17.22 and $25.93 over the past 52 weeks and currently has a market cap of $1.5 billion. Over the last eight sessions, it has gained 5.2%, rising from $21.40 to $22.51. Recent insider transactions include a $5.0 million worth of buys reported on SEC Form 4 filings, with the most recent activity occurring on August 10, 2026. The stock also printed three fresh 52-week highs and five 52-week lows on September 1, 2026, highlighting its recent volatility.

What To Watch

The stock is currently trading near its 52-week high. With multiple institutions now backing the stock, investors should monitor the breadth of coverage and any upcoming developments related to the company’s pipeline or financial updates.